Results 181 to 190 of about 196,679 (336)

Vasculitis [PDF]

JAMA Dermatology, 2018
openaire   +2 more sources

Retinal vasculitis

, 1970
JK Shrestha, Deepesh Khadka, G Lamichhane, Sushna Khanal   +3 more
openalex   +2 more sources

Metastatic carcinoma of the breast. An unusual presentation mimicking cutaneous vasculitis [PDF]

, 1987
Clay Pickard, Jeffrey P. Callen, Martin S. Blumenreich   +2 more
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Vasculitis associated with VEXAS syndrome. [PDF]

Rheumatology (Oxford)
Sullivan MM, Mead-Harvey C, Sartori-Valinotti JC, Kalantari K, Kusne YN, Patnaik MM, Mangaonkar AA, Go RS, Montes D, Reichard KK, Olteanu H, Bois MC, Hines AS, Warrington KJ, Koster MJ.   +14 more
europepmc   +1 more source

Wound, pressure ulcer, and burn guidelines (2023)―4: Guidelines for the management of connective tissue disease/vasculitis‐associated skin ulcers, third edition

The Journal of Dermatology, EarlyView.
Yoshihide Asano, Jun Asai, Takayuki Ishii, Yohei Iwata, Masanari Kodera, Chie Miyabe, Akihiko Uchiyama, Youichi Ogawa, Ken Okamura, Mari Kishibe, Yuta Koike, Yorihisa Kotobuki, Noriki Fujimoto, Takuya Miyagi, Yukie Yamaguchi, Ayumi Yoshizaki, Reiko Omori, Takeshi Nakanishi, Hiroshi Fujiwara, Takeo Maekawa, Sei‐ichiro Motegi, Yuichiro Yoshino, Minoru Hasegawa, Manabu Fujimoto, Takao Tachibana, Wound, Pressure Ulcer, and Burn Guidelines Drafting Committee (connective tissue disease/vasculitis group)   +27 more
wiley   +1 more source

GNS561 (ezurpimtrostat), a small basic lipophilic molecule, prevents lupus phenotype in a pristane‐induced lupus mouse model

British Journal of Pharmacology, EarlyView.
Background and Purpose Systemic lupus erythematosus is an autoimmune, multisystemic disease affecting all organs in the body. Accrued evidence has elucidated a role for autophagy in the onset and severity of systemic lupus erythematosus. The antimalarial drug hydroxychloroquine constitutes the cornerstone of standard of care for systemic lupus ...
Eya Toumi, Eloïne Bestion, Muriel Militello, Hubert Lepidi, Anne Plauzolles, Nathalie Bardin, Daniel Bertin, Laurent Chiche, Jean‐Louis Mege, Philippe Halfon, Soraya Mezouar   +10 more
wiley   +1 more source

CLASSIFICATION AND TREATMENT OF SYSTEMIC VASCULITIS [PDF]

, 1988
D. G. I. Scott
openalex   +1 more source

Su1004 Using Search Engine Query Data to Explore Epidemiology of Common Gastrointestinal Symptoms [PDF]

, 2016
Awad, Mohannad, Breyer, Benjamin, Day, Lukejohn, Hassid, Benjamin, Sewell, Justin L   +4 more
core   +2 more sources

Safety of an Intravitreal Bevacizumab Biosimilar (MVASI)

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background Intravitreal bevacizumab has been used off‐label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020.
Hanru Wang, Bobak Bahrami, Sonia Huang, Marzieh Tahmasebi Sarvestani, Sudha Cugati, Stewart Lake, Weng Onn Chan, Devaraj Supramaniam, Matthew Little   +8 more
wiley   +1 more source